ʻĀpono ʻia ʻo Minjuvi® (Tafasitamab) i hui pū ʻia me Lenalidomide no ka mālama ʻana i nā maʻi pākeke me ka Relapsed a i ʻole Refractory Diffuse Large B-Cell Lymphoma ma Kina.

Ma ka lā 21 o Mei, 2025, ua hoʻolaha ʻo InnoCare Pharma ua ʻae ʻia ka ʻĀina Hoʻokele Huahana Lapaʻau Lahui o Kina (NMPA) no Minjuvi® (tafasitamab), kahi antibody monoclonal CD19 i hoʻololi ʻia me ka Fc, i hui pū ʻia me lenalidomide, a ukali ʻia e ka Minjuvi monotherapy, no ka mālama ʻana i nā maʻi makua me ka lymphoma nui B-cell diffuse relapsed a refractory paha (DLBCL) ʻaʻole kūpono no ka hoʻoili ʻana o nā cell stem autologous (ASCT). ʻO kēia ka antibody CD19 mua i ʻae ʻia no ka mālama ʻana i ka DLBCL relapsed a refractory paha ma Kina.

E pili ana iā Tafasitamab

ʻO Tafasitamab kahi antibody monoclonal i hoʻololi ʻia e Fc i hoʻololi ʻia e ke kanaka. Hoʻokomo ʻo Tafasitamab i kahi kikowaena Fc i hana ʻia, ka mea e hoʻoponopono i ka lysis B-cell ma o ka apoptosis a me ka ʻano hana hoʻokō pale e komo pū ana me ka Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) a me ka Antibody-Dependent Cellular Phagocytosis (ADCP).

Ua komo ʻo MorphoSys lāua ʻo Incyte i loko o: (a) i Ianuali 2020, kahi ʻaelike hana like a me ka laikini e hoʻomohala a kūʻai aku i ka tafasitamab ma ka honua holoʻokoʻa; a me (b) i Pepeluali 2024, kahi ʻaelike kahi i loaʻa ai iā Incyte nā kuleana kūʻokoʻa e hoʻomohala a kūʻai aku i ka tafasitamab ma ka honua holoʻokoʻa.

I ʻAukake 2021, ua komo ʻo Incyte i loko o kahi ʻaelike hana like a me ka laikini me InnoCare no ka hoʻomohala ʻana a me ke kālepa kūʻokoʻa ʻana o ka tafasitamab i ka hematology a me ka oncology ma Kina Nui.

Ma ʻAmelika Hui Pū ʻIa, ua loaʻa iā Monjuvi (tafasitamab-cxix) ka ʻae wikiwiki ʻia e ka US Food and Drug Administration i hui pū ʻia me lenalidomide no ka mālama ʻana i nā maʻi makua me ka DLBCL relapsed a refractory paha i kuhikuhi ʻole ʻia, me DLBCL e kū mai ana mai ka lymphoma haʻahaʻa, a ʻaʻole kūpono no ka hoʻoili ʻana o nā cell stem autologous (ASCT). Ma ʻEulopa, ua loaʻa iā Minjuvi (tafasitamab) ka ʻAe Kūʻai Kūʻai conditional mai ka European Medicines Agency i hui pū ʻia me lenalidomide, a ukali ʻia e Minjuvi monotherapy, no ka mālama ʻana i nā maʻi makua me ka lymphoma B-cell nui diffuse relapsed a refractory paha (DLBCL) ʻaʻole kūpono no ka hoʻoili ʻana o nā cell stem autologous (ASCT).

I kēia manawa, nui nā hoʻokolohua lapaʻau o nā ʻenehana anti-cancer hou ma Kina e ʻimi nei i nā maʻi. I ke kūkākūkā ʻana i nā lāʻau lapaʻau a me nā ʻenehana hou, hiki iā ʻoe ke hoʻokaʻaʻike aku i ka Beijing South Region Oncology Hospital International Department.

Helu Kelepona：4008803716

Email：myimmnet@163.com